Liquent Unveils the Results of its Regulatory Affairs Trends Survey

Regulatory Professionals Contribute to this Global Insight into Regulatory Trends

HORSHAM, Pennsylvania, July 28, 2010 - Liquent, Inc. ("Liquent") is pleased to announce the findings of its 2009
Liquent Regulatory Affairs Trends Survey. The survey attracted respondents
from across the globe representing small, medium and large life sciences
companies and provides a unique insight into emerging and future trends in
regulatory product management usage and adoption.

Liquent's annual survey is one of the leading resources of trends
impacting regulatory affairs and operations professionals. The survey
provides insight into how pharmaceutical regulatory professionals use
technology today and how they plan to harness technology in the future. It is
recognized as the premier benchmark of global regulatory submission trends in
the market today. The survey provides exclusive insight into the emerging and
future trends of regulatory product management needs for the life science
market. The Liquent 2009 survey yielded a variety of responses from 150
Regulatory Affairs professionals.

This year's survey concentrated on four key areas: Technology Usage
Trends, including submission publishing, registration management and other
technologies, Document Management System usage, Regulatory Operations
Outsourcing trends, and Regulatory trends including adoption of electronic
Common Technical Document (eCTD) and other regulatory submission formats.

Key survey findings include:

Technology Usage:

–88% of respondents are expecting their use of publishing software to
increase over the next 2 years. This figure has increased slightly since 2008
(82%).

Regulatory Outsourcing:

–31% of respondents are outsourcing study report writing and 18% are
outsourcing study report publishing. Up from 22% and 9% respectively in 2008.

Regulatory Trends

— 14% of respondents plan to adopt the HL7's Regulated Product
Submission (RPS) format within the next two years. This figure has increased
significantly since 2008 (7%).

"Every year our regulatory trends survey attracts a varied group of
respondents from a diverse number of organizations throughout the globe, and
this year was no different," said Jim Nichols, Vice President, Strategy at
Liquent. "The findings reaffirm our belief that the continued standardization
of submission and data formats is making it easier to share critical
information both internally and with the regulatory authorities."

Liquent will be presenting its full results later this year as part of
their monthly webinar series. For additional information please contact
Liquent at info@liquent.com.

Liquent is owned by Marlin Equity Partners a Los Angeles,
California-based private investment firm with over US$1 billion of capital
under management.

About Liquent, Inc.

Liquent regulatory solutions provide software and related regulatory and
clinical services for the life sciences industry. These solutions and
services help ensure clients meet the strict standards of regulatory
authorities across the world helping them achieve quality, accuracy, and data
integrity to deliver regulatory reports and submissions reliably and on time.

As a result, global life sciences companies, small tier to large tier,
rely on Liquent regulatory solutions to provide the technology and services
to compress the regulatory submissions and approval process, improving speed
to market, cost control, and productivity, all of which contribute to
ensuring patients' and physicians' timely access to new drugs. Over the last
decade, thousands of regulatory submissions have been produced using Liquent
world-class products and expert services. For more information please visit,
www.liquent.com.

    Contact:  Jim Nichols
              Vice President, Strategy
              +1-215-328-4320

Jim Nichols, Vice President, Strategy, Liquent, Inc., +1-215-328-4320